Molecular Diagnostics at the Point of Care Market Report 2023: The COVID-19 Pandemic Drives Point of Care Diagnostics into Hypergrowth

News provided by

Jan 12, 2023, 13:45 ET

DUBLIN, Jan. 12, 2023 /PRNewswire/ -- The "Molecular Diagnostics at the Point of Care: By Application, Technology, Place, Product and by Country, with COVID-19 PoC Breakout and Executive Guides" report has been added to ResearchAndMarkets.com's offering.

The COVID-19 pandemic is ushering in a new world of point of care diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Point of Care testing move into the Physician's Office or even the Home? How much Covid-19 testing is being done at the Point of Care?

Point of Care testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time.

Market Dynamics

Market Drivers

New Genotypes Creating New Markets
Aging Population a Boon for All Diagnostics
Developing World Driving ID Dx Growth
Point of Care - Why Centralization is Losing Steam
Self Testing
The Need for Speed
The COVID Pandemic

Market Limitations

Lower Costs
Infectious Disease is Declining
Wellness Hurts
Economic Growth improves Living Standards

Key Topics Covered:

1 Market Guides

2 Introduction and Market Definition

3 The Infectious Diseases - Market Analysis by Disease
3.1 HIV - Human Immunodeficiency Virus (AIDS)
3.2 HBV - Hepatitis B
3.3 HCV - Hepatitis C
3.4 HPV - Human papillomavirus
3.5 Influenza
3.6 CTGC - Chlamydia/Gonorhea
3.7 Tuberculosis
3.8 MRSA - Methicillin-resistant Staphylococcus aureus
3.9 VRE - Vancomycin-resistant Enterococcus
3.10 Blood Screening
3.11 COVID-19
3.12 Pandemic Diagnostics

4 Industry Overview
4.1 Players in a Dynamic Market
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Instrumentation Supplier
4.1.4 Distributor and Reagent Supplier
4.1.5 Independent Testing Lab
4.1.6 Public National/regional lab
4.1.7 Hospital lab
4.1.8 Physician Office Labs and Clinics
4.1.9 Audit Body
4.1.10 Certification Body
4.2 The Clinical Laboratory Market Segments
4.2.1 Traditional Market Segmentation
4.2.2 Laboratory Focus and Segmentation
4.3 Industry Structure
4.3.1 Hospital Testing Share
4.3.2 Economies of Scale
4.3.2.1 Hospital vs. Central Lab
4.3.3 Physician Office Lab's
4.3.4 Physician's and POCT

5 Profiles of Key MDx Companies

6 Market Trends

7 Molecular Dx - Infectious Disease Recent Developments

8 The Global Market for Molecular Diagnostics at the Point of Care

9 Global MDx at the Point of Care Markets - By Application
9.1 COVID-19
9.3 Gastrointestinal Infectious Disease
9.4 Sexually Transmitted Disease
9.5 Other Application

10 Global MDx Markets at the Point of Care - by Technology
10.1 PCR
10.2 NGS/Probe
10.3 Other Technology

11 Global MDx at the Point of Care Markets - by Place
11.1 Hospital Point of Care
11.2 Clinic or Physician Office Lab
11.3 Seniors Facility
11.4 Other Place

12 Global MDx at the Point of Care Markets - by Product
12.1 Instrument
12.2 Cartridge
12.3 Other Product

Companies Mentioned

Abacus Diagnostica
Abbott Diagnostics
Accelerate Diagnostics
Ador Diagnostics
Akonni Biosystems
Alveo Technologies
Applied BioCode
Aus Diagnostics
Beckman Coulter Diagnostics
Becton, Dickinson and Company
Binx Health
Bio-Rad Laboratories, Inc
Biocartis
bioMerieux Diagnostics
Bosch Healthcare Solutions GmbH
Cepheid (now Danaher)
Chembio
Co Diagnostics
Credo Diagnostics Biomedical
Cue Health
Curetis N.V./Curetis GmbH
Diagenode Diagnostics
Diascopic
Diasorin S.p.A
Eiken Chemical
Enzo Life Sciences, Inc
Eurofins Scientific
Fluxergy
Fulgent Genetics
Fusion Genomics
Genedrive
Genetic Signatures
GenMark Dx
Grifols
Hibergene Diagnostics
Hologic
Illumina
Immunexpress
Inflammatix
Invetech
Janssen Diagnostics
Karius
Lexagene
LightDeck Diagnostics
Luminex Corp
Lumos Diagnostics
Mammoth Biosciences
Maxim Biomedical
Meridian Bioscience
Mesa Biotech
Millipore Sigma
Mindray
Mobidiag
Nanomix
Operon
Oxford Nanopore Technologies
Panagene
Perkin Elmer
Primerdesign
Prominex
Qiagen Gmbh
Quantumdx
Quidel
Roche Molecular Diagnostics
Saw Diagnostics
Seegene
Siemens Healthineers
Sona Nanotech
SpeeDx
T2 Biosystems
Thermo Fisher Scientific Inc
Veramarx
Veredus Laboratories
Vir
XCR Diagnostics

For more information about this report visit https://www.researchandmarkets.com/r/15zf3u

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets